{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Abstract\n",
    "The objective of this notebook will be to perform keyword analysis on the papers for Covid-19 risk factors."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "import re\n",
    "import glob\n",
    "import json\n",
    "from os import path\n",
    "import pandas as np\n",
    "import pandas as pd\n",
    "from datetime import datetime"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "papers_df = pd.read_csv('../output/papers_df.csv', \n",
    "                        index_col=0, \n",
    "                        keep_default_na=False,\n",
    "                       parse_dates=['publish_time'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "transmission_keywords = ['transmi', 'sneez', 'contact trac', 'reproduc', 'environ']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "smoke_keywords = ['smok']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "covid_keywords = ['COVID-19', 'HCoV-19', 'CORD-19' ,'2019-nCoV', 'Wuhan coronavirus', 'SARS-CoV-2', 'SARS-COV-2']\n",
    "covid_keywords = [word.lower() for word in covid_keywords]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "metadata": {},
   "outputs": [],
   "source": [
    "design_list = [ 'retrospective cohort', 'cross-sectional case-control','prevalence survey', \n",
    "               'systematic review , meta-analysis','matched case-control',\n",
    "               'medical records review', 'observational case series','time series analysis',\n",
    "               'pseudo-randomized controlled trials' ,'randomized controlled trials']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "# covid_papers = papers_df[papers_df['text_body'].apply(lambda x : \n",
    "#                                                 any(key in x.lower() for\n",
    "#                                                     key in covid_keywords)\n",
    "#                                                )]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "def tokenize(text):\n",
    "    text = text.lower().strip()\n",
    "    if len(text) == 0:\n",
    "        return ''\n",
    "    if text[-1] == 's':\n",
    "        text = text[:-1]\n",
    "    return text"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Creating a list of paper dictionaries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [],
   "source": [
    "json_files = glob.glob(f'../data/**/*.json', recursive=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "paper_dicts = []\n",
    "for file in json_files:\n",
    "    name = path.basename(file)\n",
    "    with open(file) as f:\n",
    "        data = json.load(f)\n",
    "    paper_obj = {'id':name,\n",
    "                 'data':data}\n",
    "    paper_dicts.append(paper_obj)    "
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Filtering for covid related papers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 81,
   "metadata": {},
   "outputs": [],
   "source": [
    "covid_papers = []\n",
    "for paper in papers:\n",
    "    body = paper['data']['body_text']\n",
    "    for paragraph in body:\n",
    "        text = paragraph['text']\n",
    "        match = any(key.lower() in text.lower()\n",
    "                   for key in covid_keywords)\n",
    "        if match:\n",
    "            covid_papers.append(paper)\n",
    "            break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "2160"
      ]
     },
     "execution_count": 82,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(covid_papers)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Analysis for different sections in the papers"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [],
   "source": [
    "sections = {}\n",
    "for paper in covid_papers:\n",
    "    body = paper['data']['body_text']\n",
    "    paper_sections = set()\n",
    "    for paragraph in body:\n",
    "        if 'section' in paragraph:\n",
    "            paper_sections.add(paragraph['section'])\n",
    "    \n",
    "    for section in paper_sections:\n",
    "        section = tokenize(section)\n",
    "        if section in sections:\n",
    "            sections[section] += 1\n",
    "        else:\n",
    "            sections[section] = 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('introduction', 883),\n",
       " ('', 821),\n",
       " ('discussion', 699),\n",
       " ('conclusion', 372),\n",
       " ('result', 331),\n",
       " ('statistical analysi', 195),\n",
       " ('(which was not peer-reviewed)', 169),\n",
       " ('method', 168),\n",
       " ('declaration of competing interest', 118),\n",
       " ('declaration of interest', 88),\n",
       " ('data collection', 82),\n",
       " ('funding', 59),\n",
       " ('background', 58),\n",
       " ('results and discussion', 51),\n",
       " ('acknowledgment', 50),\n",
       " ('contributor', 50),\n",
       " ('role of the funding source', 50),\n",
       " ('added value of this study', 42),\n",
       " ('data', 41),\n",
       " ('conflicts of interest', 41),\n",
       " ('conflict of interest', 39),\n",
       " ('study design and participant', 39),\n",
       " ('implications of all the available evidence', 38),\n",
       " ('data source', 37),\n",
       " ('data sharing', 36),\n",
       " ('materials and method', 36),\n",
       " ('research in context', 36),\n",
       " ('11', 35),\n",
       " ('acknowledgement', 35),\n",
       " ('author contribution', 31),\n",
       " ('patient', 31),\n",
       " ('5', 30),\n",
       " ('model', 28),\n",
       " ('j o u r n a l p r e -p r o o f', 27),\n",
       " ('ethical approval', 25),\n",
       " ('limitation', 25),\n",
       " ('15', 24),\n",
       " ('data analysi', 23),\n",
       " ('summary', 23),\n",
       " ('outcome', 22),\n",
       " ('9', 21),\n",
       " ('discussion and conclusion', 21),\n",
       " ('methods:', 21),\n",
       " ('10', 20),\n",
       " ('7', 20),\n",
       " ('conflicts of interest:', 19),\n",
       " ('4', 19),\n",
       " ('dear editor,', 19),\n",
       " ('6', 18),\n",
       " ('procedure', 18),\n",
       " ('study design', 18),\n",
       " ('treatment', 18),\n",
       " ('data availability', 18),\n",
       " ('results:', 17),\n",
       " ('introduction:', 17),\n",
       " ('discussion:', 17),\n",
       " ('16', 17),\n",
       " ('i. introduction', 16),\n",
       " ('ethics approval and consent to participate', 16),\n",
       " ('definition', 16),\n",
       " ('19', 16),\n",
       " ('18', 16),\n",
       " ('17', 16),\n",
       " ('8', 16),\n",
       " ('abstract', 16),\n",
       " ('contents lists available at sciencedirect', 16),\n",
       " ('statistic', 15),\n",
       " ('consent for publication', 14),\n",
       " ('availability of data and material', 14),\n",
       " ('13', 14),\n",
       " ('funding source', 14),\n",
       " ('clinical manifestation', 14),\n",
       " ('study design and patient', 13),\n",
       " ('supplementary material', 13),\n",
       " ('study population', 13),\n",
       " (\"authors' contribution\", 13),\n",
       " ('ethic', 13),\n",
       " ('participant', 13),\n",
       " ('case report', 13),\n",
       " ('phylogenetic analysi', 12),\n",
       " ('ethics statement', 12),\n",
       " ('reference', 12),\n",
       " ('sensitivity analysi', 12),\n",
       " ('interpretation', 12),\n",
       " ('cc-by-nc-nd 4.0 international license', 12),\n",
       " ('ethical consideration', 12),\n",
       " ('1. introduction', 12),\n",
       " ('ethical statement', 11),\n",
       " ('finding', 11),\n",
       " ('conclusion:', 11),\n",
       " ('prevention', 11),\n",
       " ('article in pres', 11),\n",
       " ('figure', 10),\n",
       " ('figure 2', 10),\n",
       " ('ethics approval', 10),\n",
       " ('statistical analyse', 10),\n",
       " ('1', 10),\n",
       " ('20', 10),\n",
       " ('sars-cov', 10),\n",
       " ('figure 3', 9),\n",
       " ('disclaimer', 9),\n",
       " ('sample collection', 9),\n",
       " ('competing interest', 9),\n",
       " ('incubation period', 9),\n",
       " ('12', 9),\n",
       " ('clinical feature', 9),\n",
       " ('declaration', 9),\n",
       " ('conflict of interest statement', 9),\n",
       " ('case 2', 9),\n",
       " ('editorial', 9),\n",
       " ('parameter', 8),\n",
       " ('disclosure statement', 8),\n",
       " ('123', 8),\n",
       " ('figure legend', 8),\n",
       " ('epidemiological characteristic', 8),\n",
       " ('22', 8),\n",
       " ('covid-19', 8),\n",
       " ('epidemiological data', 8),\n",
       " ('vaccine', 8),\n",
       " ('2.', 8),\n",
       " ('patient and public involvement', 8),\n",
       " ('diagnosi', 8),\n",
       " ('data and code availability', 7),\n",
       " ('material and method', 7),\n",
       " ('parameter estimation', 7),\n",
       " ('inclusion and exclusion criteria', 7),\n",
       " ('literature search', 7),\n",
       " ('27', 7),\n",
       " ('main text', 7),\n",
       " ('eligibility criteria', 7),\n",
       " ('abstract:', 7),\n",
       " ('demographic and clinical characteristic', 7),\n",
       " ('laboratory examination', 7),\n",
       " ('3', 7),\n",
       " ('molecular docking', 7),\n",
       " ('statistical model', 7),\n",
       " ('statistical method', 7),\n",
       " ('a b s t r a c t', 7),\n",
       " ('epidemiology', 7),\n",
       " ('data availability statement', 6),\n",
       " ('objective', 6),\n",
       " ('2', 6),\n",
       " ('case definition', 6),\n",
       " ('clinical characteristic', 6),\n",
       " ('172', 6),\n",
       " ('study selection', 6),\n",
       " ('table', 6),\n",
       " ('76', 6),\n",
       " ('21', 6),\n",
       " ('funding statement', 6),\n",
       " ('supplementary information', 6),\n",
       " ('data description', 6),\n",
       " ('methodology', 6),\n",
       " ('concluding remark', 6),\n",
       " ('116', 6),\n",
       " ('case 1', 6),\n",
       " ('epidemiological incidence case', 6),\n",
       " ('statistical analysis ::: method', 6),\n",
       " ('letter to the editor', 6),\n",
       " ('table 1', 6),\n",
       " ('conclusions and future direction', 5),\n",
       " ('incubation period distribution', 5),\n",
       " ('france', 5),\n",
       " ('south korea', 5),\n",
       " ('the model', 5),\n",
       " ('data extraction', 5),\n",
       " ('conflict of interest:', 5),\n",
       " ('30', 5),\n",
       " ('143', 5),\n",
       " ('26', 5),\n",
       " ('54', 5),\n",
       " ('67', 5),\n",
       " ('rna extraction', 5),\n",
       " ('model validation', 5),\n",
       " ('125', 5),\n",
       " ('256', 5),\n",
       " ('158', 5),\n",
       " ('135', 5),\n",
       " ('laboratory testing', 5),\n",
       " ('62', 5),\n",
       " ('quality assessment', 5),\n",
       " ('perspective', 5),\n",
       " ('238', 5),\n",
       " ('figure 4', 5),\n",
       " ('search strategy', 5),\n",
       " ('122', 5),\n",
       " ('3.', 5),\n",
       " ('132', 5),\n",
       " ('sars-cov-2', 5),\n",
       " ('4.', 5),\n",
       " ('164', 5),\n",
       " ('symptom', 5),\n",
       " ('strengths and limitation', 5),\n",
       " ('confirmed case', 5),\n",
       " ('authors orcid', 5),\n",
       " ('highlight', 5),\n",
       " ('4. discussion', 5),\n",
       " ('disclosure of interest', 5),\n",
       " ('dear editor', 5),\n",
       " ('introducción', 5),\n",
       " ('related work', 4),\n",
       " ('model description', 4),\n",
       " ('sensitivity analyse', 4),\n",
       " ('discussions and conclusion', 4),\n",
       " ('mathematical model', 4),\n",
       " ('disclosure', 4),\n",
       " ('111', 4),\n",
       " ('laboratory test', 4),\n",
       " ('iran', 4),\n",
       " ('united state', 4),\n",
       " ('subject', 4),\n",
       " ('clinical outcome', 4),\n",
       " ('clinical classification', 4),\n",
       " ('conclusions:', 4),\n",
       " ('summary background', 4),\n",
       " ('the data', 4),\n",
       " ('laboratory finding', 4),\n",
       " ('28', 4),\n",
       " ('24', 4),\n",
       " ('31', 4),\n",
       " ('declaration of interest statement', 4),\n",
       " ('106', 4),\n",
       " ('119', 4),\n",
       " ('definition of outbreak control', 4),\n",
       " ('model structure', 4),\n",
       " ('transmission scenario', 4),\n",
       " ('297', 4),\n",
       " ('funding:', 4),\n",
       " ('94', 4),\n",
       " ('120', 4),\n",
       " ('99', 4),\n",
       " ('clinical finding', 4),\n",
       " ('real-time reverse transcription polymerase chain reaction assay for sars-cov-2',\n",
       "  4),\n",
       " ('137', 4),\n",
       " ('81', 4),\n",
       " ('96', 4),\n",
       " ('as shown in', 4),\n",
       " ('50', 4),\n",
       " ('23', 4),\n",
       " ('demographic characteristic', 4),\n",
       " ('intervention', 4),\n",
       " ('2.2', 4),\n",
       " ('211', 4),\n",
       " ('105', 4),\n",
       " ('susceptible population', 4),\n",
       " ('route of transmission', 4),\n",
       " ('154', 4),\n",
       " ('55', 4),\n",
       " ('127', 4),\n",
       " ('social distancing', 4),\n",
       " ('232', 4),\n",
       " ('effect of screening on detection', 4),\n",
       " ('1.introduction', 4),\n",
       " ('online content', 4),\n",
       " ('conclusion and future prospect', 4),\n",
       " ('coronaviruse', 4),\n",
       " ('short-term forecast', 4),\n",
       " ('review', 4),\n",
       " ('differential diagnosi', 4),\n",
       " (\"author's contribution\", 4),\n",
       " ('conclusions and future perspective', 4),\n",
       " ('star+method', 4),\n",
       " ('strain', 4),\n",
       " ('ideas and opinion', 4),\n",
       " ('5.', 4),\n",
       " ('virology', 4),\n",
       " ('fig. 2.', 4),\n",
       " ('data, code and material', 4),\n",
       " ('limitations of this study', 3),\n",
       " ('what this study add', 3),\n",
       " ('115', 3),\n",
       " ('quantification and statistical analysi', 3),\n",
       " ('iv. discussion', 3),\n",
       " ('iii. results and discussion', 3),\n",
       " ('ii. model', 3),\n",
       " ('metapopulation model', 3),\n",
       " ('research in context evidence before this study', 3),\n",
       " ('170', 3),\n",
       " ('cell-cell interaction analysi', 3),\n",
       " ('meta-analysi', 3),\n",
       " ('case', 3),\n",
       " ('a b', 3),\n",
       " ('153', 3),\n",
       " ('presenting characteristic', 3),\n",
       " ('figure 1', 3),\n",
       " ('evidence before this study', 3),\n",
       " ('statistical modelling', 3),\n",
       " ('functional enrichment analysi', 3),\n",
       " ('demographic', 3),\n",
       " ('laboratory confirmation', 3),\n",
       " ('58', 3),\n",
       " ('33', 3),\n",
       " ('36', 3),\n",
       " ('25', 3),\n",
       " ('80', 3),\n",
       " ('152', 3),\n",
       " ('181', 3),\n",
       " ('14', 3),\n",
       " ('cell culture', 3),\n",
       " ('neonatal outcome', 3),\n",
       " ('dataset', 3),\n",
       " ('311', 3),\n",
       " ('113', 3),\n",
       " ('introduction purpose and research question', 3),\n",
       " ('data items and data abstraction', 3),\n",
       " ('protocol', 3),\n",
       " ('study selection proces', 3),\n",
       " ('synthesi', 3),\n",
       " ('risk of bias appraisal', 3),\n",
       " ('japan', 3),\n",
       " ('italy', 3),\n",
       " ('1.', 3),\n",
       " ('acknowledgements:', 3),\n",
       " ('original article', 3),\n",
       " ('275', 3),\n",
       " ('222', 3),\n",
       " ('89', 3),\n",
       " ('245', 3),\n",
       " ('special population', 3),\n",
       " ('characteristics of included studie', 3),\n",
       " ('figures and table', 3),\n",
       " ('147', 3),\n",
       " ('107', 3),\n",
       " ('156', 3),\n",
       " ('217', 3),\n",
       " ('112', 3),\n",
       " ('368', 3),\n",
       " ('261', 3),\n",
       " ('151', 3),\n",
       " ('prediction', 3),\n",
       " ('follow-up', 3),\n",
       " ('simulation', 3),\n",
       " ('83', 3),\n",
       " ('ct scan', 3),\n",
       " ('supplemental material', 3),\n",
       " ('iii. result', 3),\n",
       " ('informed consent', 3),\n",
       " ('culture', 3),\n",
       " ('setting', 3),\n",
       " ('keywords:', 3),\n",
       " ('treatment and complication', 3),\n",
       " ('212', 3),\n",
       " ('personal protective equipment (ppe)', 3),\n",
       " ('code availability', 3),\n",
       " ('estimation', 3),\n",
       " ('main text:', 3),\n",
       " ('transmission model', 3),\n",
       " ('192', 3),\n",
       " ('reverse transcription', 3),\n",
       " ('121', 3),\n",
       " ('antibody measurement', 3),\n",
       " ('china', 3),\n",
       " ('255', 3),\n",
       " ('91', 3),\n",
       " ('covid-19.', 3),\n",
       " ('229', 3),\n",
       " ('100', 3),\n",
       " ('comorbiditie', 3),\n",
       " ('53', 3),\n",
       " ('transmission cluster', 3),\n",
       " ('cluster a', 3),\n",
       " ('252', 3),\n",
       " ('search strategy and selection criteria', 3),\n",
       " ('methods and material', 3),\n",
       " ('296', 3),\n",
       " ('transmission of the viru', 3),\n",
       " ('transmission dynamic', 3),\n",
       " ('129', 3),\n",
       " ('243', 3),\n",
       " ('baseline characteristic', 3),\n",
       " ('europe', 3),\n",
       " ('model simulation', 3),\n",
       " ('acknowledgments:', 3),\n",
       " ('real-time reverse-transcription pcr', 3),\n",
       " ('specimen collection', 3),\n",
       " ('epidemic parameter', 3),\n",
       " ('2019-ncov', 3),\n",
       " ('main', 3),\n",
       " ('death', 3),\n",
       " ('authors contribution', 3),\n",
       " ('general information', 3),\n",
       " ('clinical symptom', 3),\n",
       " ('note', 3),\n",
       " ('low lym% is a predictor of prognosis in covid-19 patient', 3),\n",
       " ('laboratory result', 3),\n",
       " ('funding support', 3),\n",
       " ('simulation of travellers at each stage of infection with 2019-ncov', 3),\n",
       " ('antiviral therapy', 3),\n",
       " ('public health response', 3),\n",
       " ('prevention and control', 3),\n",
       " ('action plan and discussion', 3),\n",
       " ('travellers from wuhan with confirmed 2019 novel coronavirus infection, reported symptom onset data and reported travel history',\n",
       "  3),\n",
       " ('general treatment', 3),\n",
       " ('molecular assays for respiratory pathogen', 3),\n",
       " ('diagnostic algorithm', 3),\n",
       " ('experimental design, materials, and method', 3),\n",
       " ('data source location university campus bio-medico of rome data accessibility',\n",
       "  3),\n",
       " ('how are health agencies reacting?', 3),\n",
       " ('how are infected people being treated?', 3),\n",
       " ('why is the world health organization (who) so concerned about it?', 3),\n",
       " ('compliance with ethical standard', 3),\n",
       " ('genome sequence analysi', 3),\n",
       " ('follow-up of contact', 3),\n",
       " ('therapeutic', 3),\n",
       " ('open acces', 3),\n",
       " ('summary and perspective', 3),\n",
       " ('laboratory diagnosi', 3),\n",
       " ('diagnosis of covid-19', 3),\n",
       " ('transmission', 3),\n",
       " ('funding and support', 3),\n",
       " ('3. result', 3),\n",
       " ('clinical presentation', 3),\n",
       " ('risk factor', 3),\n",
       " ('reporting summary ::: method', 3),\n",
       " ('lancet infect dis 2020', 3),\n",
       " ('ct protocol', 3),\n",
       " ('further perspective', 3),\n",
       " ('chloroquine and hydroxychloroquine', 3),\n",
       " ('recommendation', 3),\n",
       " ('provenance and peer review', 3),\n",
       " ('diagnosis and treatment', 3),\n",
       " ('conflicto de interese', 3),\n",
       " ('declarations of interest', 3),\n",
       " ('history', 3),\n",
       " ('inactivation of coronaviruses by biocidal agents in carrier test', 3),\n",
       " ('time-dependent dynamic model', 3),\n",
       " ('parameter estimation proces', 3),\n",
       " ('process that starts with person a being infected', 3),\n",
       " ('model calibration', 3),\n",
       " ('10-days ahead forecast', 3),\n",
       " ('15-days ahead forecast', 3),\n",
       " ('5-days ahead forecast', 3),\n",
       " ('epidemiological modeling', 3),\n",
       " ('methods and result', 3),\n",
       " ('data sharing statement', 2),\n",
       " ('entity category associated genes involved in generalized interaction network',\n",
       "  2),\n",
       " ('corpus and dictionary organization', 2),\n",
       " ('categories of entity and their labels-human conclusion and enriched pathway',\n",
       "  2),\n",
       " ('identification of all entities (csse) correctly related to the subject \"coronavirus\"',\n",
       "  2),\n",
       " ('identification of genes precisely related to the subject \"coronavirus\"', 2),\n",
       " ('construction of the data interface', 2),\n",
       " ('203', 2),\n",
       " ('flow cytometry', 2),\n",
       " ('lead contact and materials availability', 2),\n",
       " ('transmission electron microscopy', 2),\n",
       " ('sequence identity analysi', 2),\n",
       " ('sars-cov protease inhibitor dataset', 2),\n",
       " ('binding affinity training set', 2),\n",
       " ('disscussion', 2),\n",
       " ('sar', 2),\n",
       " ('model and method', 2),\n",
       " ('71', 2),\n",
       " ('sequence data collection', 2),\n",
       " ('role of the funder/sponsor', 2),\n",
       " ('conflict of interest: none', 2),\n",
       " ('germany', 2),\n",
       " ('keyword', 2),\n",
       " ('implication of all the available evidence', 2),\n",
       " ('settings and participant', 2),\n",
       " ('molecular dynamic simulation', 2),\n",
       " ('scrna-seq data alignment and sample aggregating', 2),\n",
       " ('differential analysis for cluster', 2),\n",
       " ('gene functional annotation', 2),\n",
       " ('dimensionality reduction and clustering', 2),\n",
       " ('retrieval of studie', 2),\n",
       " ('findings:', 2),\n",
       " ('225', 2),\n",
       " ('statistics analysi', 2),\n",
       " ('supplementary', 2),\n",
       " ('introduction 32', 2),\n",
       " ('elisa', 2),\n",
       " ('demographic, epidemiological and clinical characteristic', 2),\n",
       " ('method:', 2),\n",
       " ('variable', 2),\n",
       " ('epidemiological parameter', 2),\n",
       " ('laboratory procedure', 2),\n",
       " ('building the drug-target network', 2),\n",
       " ('building the human protein-protein interactome', 2),\n",
       " ('gene set enrichment analysi', 2),\n",
       " ('hcov-host interactome network', 2),\n",
       " ('network proximity measure', 2),\n",
       " ('building the virus-host interactome', 2),\n",
       " ('discovery of repurposable drugs for hcov', 2),\n",
       " ('network-based drug repurposing for hcov', 2),\n",
       " ('theoretical framework', 2),\n",
       " ('the resampling method', 2),\n",
       " ('basic characteristic', 2),\n",
       " ('role of the funder/sponsor:', 2),\n",
       " ('34', 2),\n",
       " ('daily new case', 2),\n",
       " ('29', 2),\n",
       " ('32', 2),\n",
       " ('code and data availability', 2),\n",
       " ('cell type identification', 2),\n",
       " ('cell type identification in 13 human tissue', 2),\n",
       " ('cell clustering, dimensional reduction and visualization', 2),\n",
       " ('data processing, quality control and normalization', 2),\n",
       " ('expression atlas of ace2, ssrna viral receptors and other membrane proteins in 13 human tissue',\n",
       "  2),\n",
       " ('reporting', 2),\n",
       " ('funding/support', 2),\n",
       " ('clinical sample', 2),\n",
       " ('77', 2),\n",
       " ('introduction 1', 2),\n",
       " ('western blot', 2),\n",
       " ('study outcome', 2),\n",
       " ('maternal outcome', 2),\n",
       " ('estimation of model parameter', 2),\n",
       " ('179', 2),\n",
       " ('250', 2),\n",
       " ('178', 2),\n",
       " ('competing interest statement', 2),\n",
       " ('statistical inference', 2),\n",
       " ('estimation of the delay distribution', 2),\n",
       " ('molecular dynamics simulation', 2),\n",
       " ('abstract background', 2),\n",
       " ('284', 2),\n",
       " ('236', 2),\n",
       " ('66', 2),\n",
       " ('funding information', 2),\n",
       " ('study definition', 2),\n",
       " ('timeline (from the point of official approval):', 2),\n",
       " ('quality appraisal result', 2),\n",
       " ('preliminary knowledge translation plan:', 2),\n",
       " ('data items and data abstraction proces', 2),\n",
       " ('figures caption', 2),\n",
       " ('patients and sample', 2),\n",
       " ('sars-cov-2 testing', 2),\n",
       " ('248', 2),\n",
       " ('35', 2),\n",
       " ('robustness check', 2),\n",
       " ('infection prevention', 2),\n",
       " ('220', 2),\n",
       " ('90', 2),\n",
       " ('176', 2),\n",
       " ('37', 2),\n",
       " ('strengths and limitations of this study', 2),\n",
       " ('laboratory confirmation and treatment', 2),\n",
       " ('v. conclusion', 2),\n",
       " ('references:', 2),\n",
       " ('286', 2),\n",
       " ('38', 2),\n",
       " ('302', 2),\n",
       " ('materials & method', 2),\n",
       " ('control', 2),\n",
       " ('45', 2),\n",
       " ('role of funding source', 2),\n",
       " ('effective distance', 2),\n",
       " ('invasive mechanical ventilation', 2),\n",
       " ('197', 2),\n",
       " ('318', 2),\n",
       " ('241', 2),\n",
       " ('374', 2),\n",
       " ('clinical data collection', 2),\n",
       " ('financial disclosure', 2),\n",
       " ('139', 2),\n",
       " ('173', 2),\n",
       " ('protein expression and purification', 2),\n",
       " ('baseline data collection', 2),\n",
       " ('screening', 2),\n",
       " ('data extraction and analysi', 2),\n",
       " ('epidemiological and clinical characteristic', 2),\n",
       " ('flow cytometry data analysi', 2),\n",
       " ('radiologic and laboratory parameters in mild and severe or critical patient',\n",
       "  2),\n",
       " ('individual-level data on cases outside mainland china', 2),\n",
       " ('data on aggregate cases and deaths in mainland china', 2),\n",
       " ('data on infection in repatriated international wuhan resident', 2),\n",
       " ('data on cases and deaths on the diamond princess cruise ship', 2),\n",
       " ('individual-level data on early deaths from mainland china', 2),\n",
       " ('appendice', 2),\n",
       " ('imaging evaluation', 2),\n",
       " ('ii. method', 2),\n",
       " ('hydroxychloroquine dosage', 2),\n",
       " ('effect of hydroxychloroquine on viral load', 2),\n",
       " ('statistical analysis.', 2),\n",
       " ('correspondence', 2),\n",
       " ('202', 2),\n",
       " ('103', 2),\n",
       " ('47', 2),\n",
       " ('65', 2),\n",
       " ('data collection and definition', 2),\n",
       " ('clinical characteristics of patients with covid-19', 2),\n",
       " ('epidemiologic and clinical characteristic', 2),\n",
       " ('genomic comparison', 2),\n",
       " ('data processing', 2),\n",
       " ('239', 2),\n",
       " ('personal protective equipment', 2),\n",
       " ('communication', 2),\n",
       " ('glove', 2),\n",
       " ('qrt-pcr assay for sars-cov-2', 2),\n",
       " ('298', 2),\n",
       " ('82', 2),\n",
       " ('306', 2),\n",
       " ('299', 2),\n",
       " ('187', 2),\n",
       " ('disclaimer:', 2),\n",
       " ('cell culture and transfection', 2),\n",
       " ('literature review', 2),\n",
       " ('robustnes', 2),\n",
       " ('conclusion and discussion', 2),\n",
       " ('data pre-processing', 2),\n",
       " ('parameter identification', 2),\n",
       " ('what is already known on this topic', 2),\n",
       " ('353', 2),\n",
       " ('data acquisition', 2),\n",
       " ('patient information', 2),\n",
       " ('background:', 2),\n",
       " ('iv. conclusion', 2),\n",
       " ('article information', 2),\n",
       " ('supplemental figure', 2),\n",
       " ('laboratory and radiographic finding', 2),\n",
       " ('104', 2),\n",
       " ('101', 2),\n",
       " ('protein-protein docking', 2),\n",
       " ('materials and methods:', 2),\n",
       " ('viral rna preparation', 2),\n",
       " ('169', 2),\n",
       " ('234', 2),\n",
       " ('97', 2),\n",
       " ('14.', 2),\n",
       " ('figure 4:', 2),\n",
       " ('phylogenetic analyse', 2),\n",
       " ('sources of data', 2),\n",
       " ('247', 2),\n",
       " ('72', 2),\n",
       " ('data collection and processing', 2),\n",
       " ('testing regime changes:', 2),\n",
       " ('295', 2),\n",
       " ('0', 2),\n",
       " ('seir model', 2),\n",
       " ('social mixing and intervention', 2),\n",
       " ('exact solution of sir-equation', 2),\n",
       " ('128', 2),\n",
       " ('exclusion criteria', 2),\n",
       " ('acknowledgment:', 2),\n",
       " ('infection-related biomarker', 2),\n",
       " ('the simplified reservoir-people transmission network model', 2),\n",
       " ('84', 2),\n",
       " ('290', 2),\n",
       " ('276', 2),\n",
       " ('366', 2),\n",
       " ('model prediction', 2),\n",
       " ('radiologic and laboratory finding', 2),\n",
       " ('study characteristic', 2),\n",
       " ('48', 2),\n",
       " ('imputing the date of onset', 2),\n",
       " ('reconstructed incidence of covid-19', 2),\n",
       " ('estimate of reproduction number from daily case incidence', 2),\n",
       " ('effective reproduction number ( ) from daily case incidence', 2),\n",
       " ('data and method', 2),\n",
       " ('264', 2),\n",
       " ('image acquisition', 2),\n",
       " ('/ 18', 2),\n",
       " ('flow cytometry analysi', 2),\n",
       " ('research design', 2),\n",
       " ('124', 2),\n",
       " ('the simulation of daily new infection', 2),\n",
       " ('cure the discharge proces', 2),\n",
       " ('analysis of iranian data', 2),\n",
       " ('simulation of the number of the average infected people', 2),\n",
       " ('death toll', 2),\n",
       " ('simulation of the number of infected people', 2),\n",
       " ('the simulation test of the epidemic control', 2),\n",
       " ('simulation comparison of epidemic model in hubei province', 2),\n",
       " ('analysis of italian data', 2),\n",
       " ('specific analysis of the epidemic situation model', 2),\n",
       " ('analysis of korea data', 2),\n",
       " ('analysi', 2),\n",
       " ('virus isolation', 2),\n",
       " ('data extraction and paper quality evaluation', 2),\n",
       " ('plasmid', 2),\n",
       " ('177', 2),\n",
       " ('342', 2),\n",
       " ('model equation', 2),\n",
       " ('estimation of basic reproduction number (r0)', 2),\n",
       " ('118', 2),\n",
       " ('175', 2),\n",
       " ('214', 2),\n",
       " ('69', 2),\n",
       " ('140', 2),\n",
       " ('cell line', 2),\n",
       " ('internal validation', 2),\n",
       " ('personnel training', 2),\n",
       " ('10)', 2),\n",
       " ('324', 2),\n",
       " ('estimating detection probability relative to singapore', 2),\n",
       " ('respiratory support', 2),\n",
       " ('patient cohort', 2),\n",
       " ('model parameter', 2),\n",
       " ('338', 2),\n",
       " ('138', 2),\n",
       " ('63', 2),\n",
       " ('136', 2),\n",
       " ('231', 2),\n",
       " ('356', 2),\n",
       " ('257', 2),\n",
       " ('205', 2),\n",
       " ('42', 2),\n",
       " ('scenario', 2),\n",
       " ('59', 2),\n",
       " ('cluster c', 2),\n",
       " ('cluster b', 2),\n",
       " ('data sharing:', 2),\n",
       " ('contribution', 2),\n",
       " ('transparency declaration', 2),\n",
       " ('95', 2),\n",
       " ('350', 2),\n",
       " ('quantitative reverse transcription polymerase chain reaction', 2),\n",
       " ('calculation of absolute humidity', 2),\n",
       " ('correlation between covid-19 mortality and meteorological factors and air pollutant',\n",
       "  2),\n",
       " ('epidemiological modelling', 2),\n",
       " ('parameter selection and estimate', 2),\n",
       " ('state transition matrix model', 2),\n",
       " ('114', 2),\n",
       " ('240', 2),\n",
       " ('clinical data', 2),\n",
       " ('380', 2),\n",
       " ('patient characteristic', 2),\n",
       " ('influenza testing', 2),\n",
       " ('rt-qpcr', 2),\n",
       " ('endpoint', 2),\n",
       " ('positive control', 2),\n",
       " ('suspected patient', 2),\n",
       " ('text', 2),\n",
       " ('study limitation', 2),\n",
       " ('rna library construction and sequencing', 2),\n",
       " ('availability of data', 2),\n",
       " ('legend', 2),\n",
       " ('results & discussion', 2),\n",
       " ('incidence of aki and in-hospital death', 2),\n",
       " ('41', 2),\n",
       " ('130', 2),\n",
       " ('9 6', 2),\n",
       " ('2 8', 2),\n",
       " ('chest ct scan', 2),\n",
       " ('measure', 2),\n",
       " (\"authors' contributions:\", 2),\n",
       " ('temporal and spatial distribution and risk analysi', 2),\n",
       " ('sample collection and detection of sars-cov-2', 2),\n",
       " ('the proposed method', 2),\n",
       " ('clinical information', 2),\n",
       " ('figures and legend', 2),\n",
       " ('reduced number of exported case', 2),\n",
       " ('time delay to a major epidemic gained from the reduction in travel volume',\n",
       "  2),\n",
       " ('reduced probability of a major epidemic oversea', 2),\n",
       " ('prediction of drug-target interactions using binding affinity score', 2),\n",
       " ('amino acid sequences used in this study', 2),\n",
       " ('expertise for coronavirus and other respiratory pathogen', 2),\n",
       " ('capacity for novel coronavirus molecular diagnostic', 2),\n",
       " ('diagnostic challenge', 2),\n",
       " ('survey', 2),\n",
       " ('instructions and guidelines for mental health services during the covid-19 outbreak',\n",
       "  2),\n",
       " ('mental health issues during the covid-19 outbreak', 2),\n",
       " ('clinical services for patients with severe mental illnesses during the covid-19 outbreak',\n",
       "  2),\n",
       " ('specific measures in mental health services during the covid-19 outbreak',\n",
       "  2),\n",
       " ('the covid-19 outbreak', 2),\n",
       " ('duration of travel 12 hour', 2),\n",
       " ('mental health care', 2),\n",
       " ('supportive care', 2),\n",
       " ('radiography', 2),\n",
       " ('the outbreak', 2),\n",
       " ('pathology', 2),\n",
       " ('discrimination of 2019 novel coronavirus from sars coronavirus by rdrp assay',\n",
       "  2),\n",
       " ('protocol options and application note', 2),\n",
       " ('detection range for sars-related coronaviruses from bat', 2),\n",
       " ('clinical samples and coronavirus cell culture supernatants for initial assay evaluation',\n",
       "  2),\n",
       " ('cross-reactivity with other coronaviruse', 2),\n",
       " ('exclusivity of 2019 novel coronavirus based on clinical samples pre-tested positive for other respiratory viruse',\n",
       "  2),\n",
       " ('sensitivity based on in vitro-transcribed rna identical to 2019 novel coronavirus target sequence',\n",
       "  2),\n",
       " ('assay sensitivity based on sars coronavirus virion', 2),\n",
       " ('chemical stability', 2),\n",
       " ('2019-ncov in context: lessons learned?', 2),\n",
       " ('laboratory and diagnostic support', 2),\n",
       " ('clinical and infection control guidance', 2),\n",
       " ('data reporting', 2),\n",
       " ('reporting summary', 2),\n",
       " ('serological test', 2),\n",
       " ('article', 2),\n",
       " ('n/a confirmed', 2),\n",
       " ('trends in daily laboratory-confirmed and suspected covid-19 cases and internet data',\n",
       "  2),\n",
       " ('c o r r e s p o n d e n c e o p e n a c c e s ', 2),\n",
       " ('geo-positioning of data', 2),\n",
       " ('usage note', 2),\n",
       " ('data record', 2),\n",
       " ('background & summary', 2),\n",
       " ('technical validation', 2),\n",
       " ('fig. 3. a) and b) model of sars-cov-2 structure provided by swissmodel and visualized with jmol.',\n",
       "  2),\n",
       " ('transmission characteristics of the 2019 novel coronaviru', 2),\n",
       " ('comparison with past emergences of respiratory viruse', 2),\n",
       " ('simulating early outbreak trajectorie', 2),\n",
       " ('information on cases after creation of the national health commission task force on 18 january',\n",
       "  2),\n",
       " ('early information on 2019-ncov infections as at 12 january', 2),\n",
       " ('early outbreak of viral pneumonia of unknown aetiology as at 9 january', 2),\n",
       " ('risk of fatality among hospitalised case', 2),\n",
       " ('comparison of two hypothetical scenarios: one with large zoonotic spillover and one with small zoonotic spillover',\n",
       "  2),\n",
       " ('information on exported cases identified outside mainland china as at 17 january',\n",
       "  2),\n",
       " ('case description', 2),\n",
       " ('detected confirmed case', 2),\n",
       " ('negligible risk', 2),\n",
       " ('contact and co-exposition tracing', 2),\n",
       " ('level of risk of infection', 2),\n",
       " ('french surveillance system', 2),\n",
       " ('investigation team', 2),\n",
       " ('low risk', 2),\n",
       " ('contact and co-exposure tracing', 2),\n",
       " ('covid-19 cases in eu/eea countries and the uk', 2),\n",
       " ('obtaining cumulative number and cumulative incidence of covid-19 case', 2),\n",
       " ('trends of covid-19 in eu/eea countries and the uk', 2),\n",
       " ('take full advantage of the infection control system', 2),\n",
       " ('avoid unnecessary contact', 2),\n",
       " ('establish a scientific, reasonable shift schedule', 2),\n",
       " ('provide intense education and training for nurse', 2),\n",
       " ('provide psychological counseling', 2),\n",
       " ('utilization of network platform', 2),\n",
       " ('protection of medical staff', 2),\n",
       " ('current understanding of viral induced exacerbation of chronic airway inflammatory disease',\n",
       "  2),\n",
       " ('clinical significance of identifying additional mechanisms of acute exacerbation',\n",
       "  2),\n",
       " ('significance of virus infection in exacerbation of chronic airway inflammatory disease',\n",
       "  2),\n",
       " ('conclusion and future outlook', 2),\n",
       " ('treatment strategies against 2019-ncov', 2),\n",
       " ('amendments from version 1 introduction', 2),\n",
       " ('proposal for new 2019-ncov therapie', 2),\n",
       " ('ace2 immunoadhesin strategy', 2),\n",
       " ('sequence analysi', 2),\n",
       " (\"comparison of 2019 novel coronavirus, severe acute respiratory syndrome and middle east respiratory syndrome coronaviruses' incubation period\",\n",
       "  2),\n",
       " ('expression of ace2 in human tissues and implications for virus transmission',\n",
       "  2),\n",
       " ('unique rbd structure in 2019-ncov', 2),\n",
       " ('distribution of ace2 in the animal kingdom and implications for virus reservoir',\n",
       "  2),\n",
       " ('general sequence characteristics of 2019-ncov in comparison with sars-cov',\n",
       "  2),\n",
       " ('protection and transfer', 2),\n",
       " ('diagnostic criteria', 2),\n",
       " ('perspectives on the development of neutralizing antibodies against sars-cov-2',\n",
       "  2),\n",
       " ('similarity of sars-cov-2 and sars-cov in antigen and receptor recognition by host',\n",
       "  2),\n",
       " ('innate and adaptive responses of human to sars-cov-2 and sars-cov', 2),\n",
       " ('advances in the development of neutralizing antibodies to sars-cov', 2),\n",
       " ('looking ahead', 2),\n",
       " ('challenge', 2),\n",
       " ('epidemiology summary', 2),\n",
       " ('public datasets acquisition and analysi', 2),\n",
       " ('cardiovascular disease', 2),\n",
       " ('comparison of one-step rt-pcr system', 2),\n",
       " ('timely implementation of molecular diagnostics for sars-cov-2', 2),\n",
       " ('workflow', 2),\n",
       " ('epidemiological description and data', 2),\n",
       " ('asymptomatic carriers: fact or fiction?', 2),\n",
       " ('concluding remarks and future perspective', 2),\n",
       " ('discovery of hcov', 2),\n",
       " ('lessons from hiv', 2),\n",
       " ('animal hosts of hcov', 2),\n",
       " ('bats as a reservoir of emerging viral pathogens of human', 2),\n",
       " ('clinical presentation and laboratory confirmation of the case', 2),\n",
       " ('sars-cov-2/finland/1/2020 virus isolation', 2),\n",
       " ('analysis of possible reasons for lymphopenia in covid-19 patient', 2),\n",
       " ('establishment of a time-lym% model from discharged covid-19 patient', 2),\n",
       " ('validation of tlm in disease classification in hospitalized covid-19 patient',\n",
       "  2),\n",
       " ('lym% indicates disease severity of covid-19 patient', 2),\n",
       " ('limitations of the study', 2),\n",
       " ('basic reproductive number', 2),\n",
       " ('advances and prospects in developing vaccines and therapeutic', 2),\n",
       " ('prevention and control measure', 2),\n",
       " ('the emergence of novel-coronavirus (2019-ncov)', 2),\n",
       " ('estimated importation risk from wuhan before the travel ban in hubei province',\n",
       "  2),\n",
       " ('modelling risk of importation', 2),\n",
       " ('estimated importation risk from considered areas of china following the travel ban in hubei province',\n",
       "  2),\n",
       " ('tracking online heroisation and blame in epidemic', 2),\n",
       " ('control and mitigation measure', 2),\n",
       " ('disease severity and immunity', 2),\n",
       " ('the possible transmission routes of 2019-ncov', 2),\n",
       " ('characteristics of 2019 novel coronaviru', 2),\n",
       " ('sars-cov-2 utility channel test setup', 2),\n",
       " ('sars-cov-2 utility channel test performance evaluation', 2),\n",
       " ('information diet in crisis condition', 2),\n",
       " ('comment', 2),\n",
       " ('treatment regimen and prognosi', 2),\n",
       " ('laboratory tests and imaging examination', 2),\n",
       " ('mers-cov', 2),\n",
       " ('baseline situation for the scenario', 2),\n",
       " ('potential scenarios for the progression of the covid-19 epidemic', 2),\n",
       " ('estimation of risk of transmission', 2),\n",
       " ('implication of autophagy in covs infection', 2),\n",
       " ('brief introduction of the autophagy and the endocytic pathway', 2),\n",
       " ('involvement of the endocytic pathway in covs infection', 2),\n",
       " ('brief introduction of the new coronaviruse', 2),\n",
       " ('data compilation', 2),\n",
       " ('study design and chinese data source', 2),\n",
       " ('epidemiology of first cases in the european region', 2),\n",
       " ('surveillance in the who european region', 2),\n",
       " ('authoritarianism, outbreaks, and information politic', 2),\n",
       " ('previous epidemics caused by coronaviruse', 2),\n",
       " ('a lesson for the future', 2),\n",
       " ('chest imaging', 2),\n",
       " ('suspected case', 2),\n",
       " ('conventional treatment of sars-cov-2: is there a room for chinese medicine?',\n",
       "  2),\n",
       " ('identification of anti-novel coronaviral compound from traditional chinese medicine',\n",
       "  2),\n",
       " ('traditional chinese medicine used in the treatment of sars-cov-2-infected patients: the current situation',\n",
       "  2),\n",
       " ('traditional chinese medicine in the treatment of patients infected with sars-cov: clinical evidence',\n",
       "  2),\n",
       " ('closing remark', 2),\n",
       " ('salvage corticosteroids treatment for critical patients with 2019-ncov?',\n",
       "  2),\n",
       " ('precautions of corticosteroids treatment in patients with 2019-ncov', 2),\n",
       " ('current evidence: clinical benefits of corticosteroids therapy for critical ncp patient',\n",
       "  2),\n",
       " ('introduction and background', 2),\n",
       " ('prioritize refund', 2),\n",
       " ('move networking online', 2),\n",
       " ('give recognition', 2),\n",
       " ('cover remaining expense', 2),\n",
       " ('go virtual', 2),\n",
       " ('livestream for remote participation', 2),\n",
       " ('pathogenic mechanism', 2),\n",
       " ('concept', 2),\n",
       " ('editorial note', 2),\n",
       " ('demographics, comorbidities and outcome', 2),\n",
       " ('host and reservoir', 2),\n",
       " ('antibiotic therapy', 2),\n",
       " ('ethical statement ::: method', 2),\n",
       " ('data ::: method', 2),\n",
       " ('limitations ::: discussion', 2),\n",
       " ('statistical analysis ::: materials and method', 2),\n",
       " ('5. conclusion', 2),\n",
       " ('6. conclusion', 2),\n",
       " ('study design ::: method', 2),\n",
       " ('sequence analysis ::: materials and method', 2),\n",
       " ('participants ::: method', 2),\n",
       " ('data reporting ::: method', 2),\n",
       " ('19.', 2),\n",
       " ('wie schlimm wird es werden?', 2),\n",
       " ('nimmt die infektiosität im verlauf zu?', 2),\n",
       " ('übertragung von mensch zu mensch', 2),\n",
       " ('was tun bei verdacht?', 2),\n",
       " ('hohe mutationsraten und geringe wirtsspezifität', 2),\n",
       " ('klinische manifestation der erkrankung', 2),\n",
       " ('radiologische befunde', 2),\n",
       " ('demographic data', 2),\n",
       " ('take-home point', 2),\n",
       " ('convalescent plasma therapy', 2),\n",
       " ('monoclonal antibody', 2),\n",
       " ('mesenchymal stem cell', 2),\n",
       " ('■ reference', 2),\n",
       " ('estrategia terapéutica del srni en el covid-19', 2),\n",
       " ('recomendaciones específicas según el tipo de srni', 2),\n",
       " ('resumen', 2),\n",
       " ('elección del tipo de interfase:', 2),\n",
       " ('epidemiology of covid-19', 2),\n",
       " ('other', 2),\n",
       " ('* sı supporting information', 2),\n",
       " ('why africa should be prepared', 2),\n",
       " ('preparednes', 2),\n",
       " ('patient consent for publication', 2),\n",
       " ('in brief', 2),\n",
       " ('active learning (al)', 2),\n",
       " ('multitudinal and multimodal data', 2),\n",
       " ('cross-population train/test ai-driven model', 2),\n",
       " ('animal models for vaccine evaluation', 2),\n",
       " ('passive immunization', 2),\n",
       " ('cell culture system', 2),\n",
       " ('\\uf0b7\\uf020', 2),\n",
       " ('lesion distribution', 2),\n",
       " ('mouse coronaviruses and ocular implication', 2),\n",
       " ('feline coronaviruses and ocular manifestation', 2),\n",
       " ('human coronaviruses and the evidence for ocular manifestation', 2),\n",
       " ('the coronavirus structure and host', 2),\n",
       " ('antiviral agent', 2),\n",
       " ('corticosteroid', 2),\n",
       " ('develop a strategy for patient volume and complexity', 2),\n",
       " ('develop a robust, transparent, and open communication policy', 2),\n",
       " ('define a strategy to allocate health care resource', 2),\n",
       " ('protect and support health care workers on the front line', 2),\n",
       " ('early lessons from the frontline of the 2019-ncov outbreak', 2),\n",
       " (\"dé claration de liens d'inté rêt\", 2),\n",
       " ('■ introduction', 2),\n",
       " ('sequence alignment and modeling', 2),\n",
       " ('mechanism', 2),\n",
       " ('lysosomotropic mechanism', 2),\n",
       " ('species differences in metabolism', 2),\n",
       " ('signs and symptom', 2),\n",
       " ('management', 2),\n",
       " ('tratamiento', 2),\n",
       " ('epidemiología', 2),\n",
       " ('compliance and ethic', 2),\n",
       " ('non-invasive ventilation', 2),\n",
       " ('2.3', 2),\n",
       " ('2.4', 2),\n",
       " ('confirmed covid-19 case', 2),\n",
       " ('possible coping strategie', 2),\n",
       " ('related risk factor', 2),\n",
       " ('lessons to learn', 2),\n",
       " ('quarantine', 2),\n",
       " ('electronic supplementary material', 2),\n",
       " ('practice points from an indian perspective', 2),\n",
       " ('\\uf0b7', 2),\n",
       " ('nations and local institutions could better integrate human health within sustainable development planning',\n",
       "  2),\n",
       " ('synergies, trade-offs, and leverage', 2),\n",
       " ('environmental change, sustainable development', 2),\n",
       " ('medical waste management', 2),\n",
       " ('epidemiological investigation', 2),\n",
       " ('to the editor,', 2),\n",
       " ('to the editor', 2),\n",
       " ('the novel covid-19 viru', 2),\n",
       " ('the genome of the covid-19 viru', 2),\n",
       " ('statement of conflict of interest', 2),\n",
       " ('declaration of conflicting interest', 2),\n",
       " ('treatment and management', 2),\n",
       " ...]"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sorted(sections.items(), key=lambda x: x[1], reverse=True)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Sections vs Designs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "design_secs = {}\n",
    "for paper in covid_papers:\n",
    "    body = paper['data']['body_text']\n",
    "    relevant = set()\n",
    "    for paragraph in body:\n",
    "        text = paragraph['text']\n",
    "        if(any(design in text.lower() for design in design_list)):\n",
    "            relevant.add(paragraph['section'])\n",
    "    for section in relevant:\n",
    "        section = tokenize(section)\n",
    "        if section in design_secs:\n",
    "            design_secs[section] += 1\n",
    "        else:\n",
    "            design_secs[section] = 1"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Frequency table of sections where at least one of the designs appeared the most times"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 86,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('', 8),\n",
       " ('discussion', 7),\n",
       " ('introduction', 3),\n",
       " ('method', 2),\n",
       " ('eligibility criteria', 2),\n",
       " ('inclusion and exclusion criteria', 2),\n",
       " ('traditional chinese medicine in the treatment of patients infected with sars-cov: clinical evidence',\n",
       "  2),\n",
       " ('study design and participant', 2),\n",
       " ('treatment', 2),\n",
       " ('controls. 215', 1),\n",
       " ('literature search', 1),\n",
       " ('quality of included studie', 1),\n",
       " ('statistical analyse', 1),\n",
       " ('(which was not peer-reviewed)', 1),\n",
       " ('background', 1),\n",
       " ('ongoing human trials for covid-19', 1),\n",
       " ('strengths and limitations of this study', 1),\n",
       " ('data sources and data extraction', 1),\n",
       " ('description of studie', 1),\n",
       " ('methods:', 1),\n",
       " ('covid-19 case definitions:', 1),\n",
       " ('therapeutic', 1),\n",
       " ('study identification and selection', 1),\n",
       " ('potential therapeutic', 1),\n",
       " ('previous epidemics caused by coronaviruse', 1),\n",
       " (\"guideline's structural setup and refining the topics and coverage of this guideline\",\n",
       "  1),\n",
       " ('drug treatment 6.3.1 antiviral treatment', 1),\n",
       " ('2.6.1 general notes ::: 2.6 literature searching and preparation of evidence profiles ::: 2 guideline methodology',\n",
       "  1),\n",
       " ('6.3.1 antiviral treatment ::: 6.3 drug treatment ::: 6 treatment and control',\n",
       "  1),\n",
       " ('the emergence of covid-19 caused by sars-cov-2', 1),\n",
       " ('study selection and data extraction', 1),\n",
       " ('discussion and rationale:', 1),\n",
       " ('information source', 1),\n",
       " ('remdesivir', 1),\n",
       " ('arbidol', 1),\n",
       " ('ademdum', 1),\n",
       " ('methodologic consideration', 1),\n",
       " ('treatment of coronaviruse', 1),\n",
       " ('added value of this study', 1),\n",
       " ('158', 1),\n",
       " ('perspective', 1),\n",
       " ('melatonin effects in cytokine levels in human', 1),\n",
       " (\"the largest clinical data[48] from china's centers for disease control and prevention\",\n",
       "  1),\n",
       " ('oncological impact of deferral', 1),\n",
       " ('omission of rt:', 1),\n",
       " ('chloroquine/hydroxychloroquine', 1),\n",
       " ('corticosteroids and nsaid', 1)]"
      ]
     },
     "execution_count": 86,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sorted(design_secs.items(), key=lambda x: x[1], reverse=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.1"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
